赛诺菲喜保宁是什么药？

The U.S. FDA officially approved it as a monotherapy for pediatric patients aged 1 month to 2 years old on August 21, 2009. Its potential efficacy in the treatment of infantile spasms outweighs its potential risk of vision loss. Therefore, Vigabatrin is also used as an adjuvant therapy (CPS) to treat adult patients with refractory complex partial epilepsy.

The FDA approved the generic version of Sabril (vigabatrin) on January 16, 2019. Vigabatrin is sold under the brand name Sabril in Canada, Mexico, and the United Kingdom. Sabrilex is a Danish brand name.

Vigabatrin (vigabatrin tablets) is an analog of γ-aminobutyric acid (GABA), which can irreversibly and specifically combine with GABA aminotransferase to increase the concentration of GABA in the brain, thereby fighting epilepsy. Vigabatrin can be used as an adjuvant treatment for patients who are ineffective with other anti-epileptic drugs, and can also be used to treat patients with partial seizures (mainly used to control complex partial seizures). Vigabatrin (vigabatrin tablets) is also effective for babies with West syndrome (infant spasms), a condition for which conventional anti-epileptic drugs are usually ineffective.

Sanofi is a leading global pharmaceutical and health company that researches, develops and promotes innovative treatment solutions based on patient needs. Sanofi's main businesses cover three areas: pharmaceuticals, human vaccines and animal health. According to Medical Companion Travel, we learned that the price of French Sanofi (vigabatrin) with a specification of 500 mg x 100 tablets is around $1,450 per box. Since exchange rates fluctuate and prices are not fixed, please consult Medical Travel for specific prices.